Iclusig Approved in Japan to Treat Select Leukemia and Lymphoma Patients with Refractory Disease
News
ARIAD Pharmaceuticals has announced that Iclusig (ponatinib) was approved by the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) for the treatment of chronic myeloid leukemia (CML) resistant or intolerant to ... Read more